BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016;65:1109-23. [DOI: 10.1016/j.metabol.2016.05.003] [Cited by in Crossref: 226] [Cited by in F6Publishing: 195] [Article Influence: 37.7] [Reference Citation Analysis]
Number Citing Articles
1 Duan SJ, Ren ZY, Zheng T, Peng HY, Niu ZH, Xia H, Chen JL, Zhou YC, Wang RR, Yao SK. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease. World J Gastroenterol 2022; 28(36): 5364-5379 [DOI: 10.3748/wjg.v28.i36.5364] [Reference Citation Analysis]
2 Yi M, Peng W, Feng X, Teng F, Tang Y, Kong Q, Chen Z. Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses. Aliment Pharmacol Ther 2022. [PMID: 35989292 DOI: 10.1111/apt.17165] [Reference Citation Analysis]
3 Wang S, Shan T, Zhu J, Jiang Q, Gu L, Sun J, Bao Y, Deng B, Wang H, Wang L. Mediation Effect of Body Mass Index on the Association of Urinary Nickel Exposure with Serum Lipid Profiles. Biol Trace Elem Res 2022. [PMID: 35915279 DOI: 10.1007/s12011-022-03375-4] [Reference Citation Analysis]
4 Huang J, Zhang Z, Hao C, Qiu Y, Tan R, Liu J, Wang X, Yang W, Qu H. Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor. Front Pharmacol 2022;13:804189. [DOI: 10.3389/fphar.2022.804189] [Reference Citation Analysis]
5 Zhao Y. Association between apolipoprotein B/A1 and the risk of metabolic dysfunction associated fatty liver disease according to different lipid profiles in a Chinese population: A cross-sectional study. Clin Chim Acta 2022;534:138-45. [PMID: 35905837 DOI: 10.1016/j.cca.2022.07.014] [Reference Citation Analysis]
6 Lee J, Kwon Y, Park K, Lee HS, Park H, Han JH, Ahn SB. Metabolic Score for Insulin Resistance Is Inversely Related to Incident Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2022;14:3039. [DOI: 10.3390/nu14153039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Li B, Su R, Yan H, Liu J, Gao C, Li X, Wang C. Immunological risk factors for nonalcoholic fatty liver disease in patients with psoriatic arthritis: New predictive nomograms and natural killer cells. Front Immunol 2022;13:907729. [DOI: 10.3389/fimmu.2022.907729] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Muzurović E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension 2022;79:1319-26. [PMID: 35465684 DOI: 10.1161/HYPERTENSIONAHA.122.17982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Faraji S, Hosseini Azar MRM, Alizadeh M. Brewed chicory leaf consumption has unexpected side effects along beneficial effects on liver enzymes in non-alcoholic fatty liver disease patients. Journal of Herbal Medicine 2022;34:100572. [DOI: 10.1016/j.hermed.2022.100572] [Reference Citation Analysis]
10 Abdallah M, Brown L, Provenza J, Tariq R, Gowda S, Singal AK. Safety and efficacy of dyslipidemia treatment in NAFLD Patients: a Meta-analysis of randomized controlled trials. Ann Hepatol 2022;:100738. [PMID: 35781090 DOI: 10.1016/j.aohep.2022.100738] [Reference Citation Analysis]
11 Li P, Hu J, Zhao H, Feng J, Chai B. Multi-Omics Reveals Inhibitory Effect of Baicalein on Non-Alcoholic Fatty Liver Disease in Mice. Front Pharmacol 2022;13:925349. [DOI: 10.3389/fphar.2022.925349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Siemienowicz KJ, Filis P, Thomas J, Fowler PA, Duncan WC, Rae MT. Hepatic Mitochondrial Dysfunction and Risk of Liver Disease in an Ovine Model of “PCOS Males”. Biomedicines 2022;10:1291. [DOI: 10.3390/biomedicines10061291] [Reference Citation Analysis]
13 Aghemo A, Alekseeva OP, Angelico F, Bakulin IG, Bakulina NV, Bordin D, Bueverov AO, Drapkina OM, Gillessen A, Kagarmanova EM, Korochanskaya NV, Kucheryavii UA, Lazebnik LB, Livzan MA, Maev IV, Martynov AI, Osipenko MF, Sas EI, Starodubova A, Uspensky YP, Vinnitskaya EV, Yakovenko EP, Yakovlev AA. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. Annals of Medicine 2022;54:1548-60. [DOI: 10.1080/07853890.2022.2069854] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Shao J, Ge T, Wei Y, Zhou Y, Shi M, Liu H, Chen Z, Xia Y. Co-interventions with Clostridium butyricum and soluble dietary fiber targeting the gut microbiota improve MAFLD via the Acly/Nrf2/NF-κB signaling pathway. Food Funct 2022;13:5807-19. [PMID: 35543143 DOI: 10.1039/d1fo04224f] [Reference Citation Analysis]
15 Jiménez-Osorio AS, Jaen-Vega S, Fernández-Martínez E, Ortíz-Rodríguez MA, Martínez-Salazar MF, Jiménez-Sánchez RC, Flores-Chávez OR, Ramírez-Moreno E, Arias-Rico J, Arteaga-García F, Estrada-Luna D. Antiretroviral Therapy-Induced Dysregulation of Gene Expression and Lipid Metabolism in HIV+ Patients: Beneficial Role of Antioxidant Phytochemicals. Int J Mol Sci 2022;23:5592. [PMID: 35628408 DOI: 10.3390/ijms23105592] [Reference Citation Analysis]
16 Abd‐elrazek AM, Ibrahim SR, El‐dash HA. The ameliorative effect of Apium graveolens & curcumin against Non-alcoholic fatty liver disease induced by high fructose-high fat diet in rats. Futur J Pharm Sci 2022;8. [DOI: 10.1186/s43094-022-00416-6] [Reference Citation Analysis]
17 Gao J, Ma L, Yin J, Liu G, Ma J, Xia S, Gong S, Han Q, Li T, Chen Y, Yin Y. Camellia (Camellia oleifera bel.) seed oil reprograms gut microbiota and alleviates lipid accumulation in high fat-fed mice through the mTOR pathway. Food Funct 2022;13:4977-92. [PMID: 35452062 DOI: 10.1039/d1fo04075h] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Radbakhsh S, Katsiki N, Santos RD, Mikhailidis DP, Mantzoros CS, Sahebkar A. Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation. Metabolism 2022;:155211. [PMID: 35533891 DOI: 10.1016/j.metabol.2022.155211] [Reference Citation Analysis]
19 Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Curr Atheroscler Rep 2022. [PMID: 35507279 DOI: 10.1007/s11883-022-01028-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wu H, He X, Li Q, Zheng Y, Rayamajhi S, Thapa A, Meng G, Zhang Q, Liu L, Wu H, Gu Y, Zhang S, Zhang T, Wang X, Zhang J, Cao Z, Dong J, Zheng X, Zhang X, Dong X, Sun S, Wang X, Zhou M, Jia Q, Song K, Chang H, Niu K. Relationship between the consumption of wholegrain and nonalcoholic fatty liver disease: The TCLSIH cohort study. Clinical Nutrition 2022. [DOI: 10.1016/j.clnu.2022.05.009] [Reference Citation Analysis]
21 Liao X, Ma Q, Wu T, Shao C, Lin Y, Sun Y, Feng S, Wang W, Ye J, Zhong B. Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study. Diabetes Metab Syndr Obes 2022;15:1173-84. [PMID: 35464261 DOI: 10.2147/DMSO.S356371] [Reference Citation Analysis]
22 Passos E, Pereira C, Gonçalves IO, Faria A, Ascensão A, Monteiro R, Magalhães J, Martins MJ. Physical exercise positively modulates nonalcoholic steatohepatitis-related hepatic endoplasmic reticulum stress. J Cell Biochem 2022. [PMID: 35467032 DOI: 10.1002/jcb.30250] [Reference Citation Analysis]
23 Li M, Xie F, Wang L, Zhu G, Qi LW, Jiang S. Celastrol: An Update on Its Hepatoprotective Properties and the Linked Molecular Mechanisms. Front Pharmacol 2022;13:857956. [PMID: 35444532 DOI: 10.3389/fphar.2022.857956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Yang Q, Zhang L, Li Q, Gu M, Qu Q, Yang X, Yi Q, Gu K, Kuang L, Hao M, Xu J, Yang H. Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus. BMC Microbiol 2022;22. [DOI: 10.1186/s12866-022-02526-w] [Reference Citation Analysis]
25 Cui J, Wang Y, Xue H. Long non-coding RNA GAS5 contributes to the progression of nonalcoholic fatty liver disease by targeting the microRNA-29a-3p/NOTCH2 axis. Bioengineered 2022;13:8370-81. [PMID: 35322757 DOI: 10.1080/21655979.2022.2026858] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Zou Y, Hu C, Kuang M, Chai Y. Remnant cholesterol/high-density lipoprotein cholesterol ratio is a new powerful tool for identifying non-alcoholic fatty liver disease. BMC Gastroenterol 2022;22:134. [PMID: 35331166 DOI: 10.1186/s12876-022-02216-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
27 Gluvic Z, Tomasevic R, Bojovic K, Obradovic M, Isenovic ER. Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. Emergency and Critical Care Medicine 2022;2:12-22. [DOI: 10.1097/ec9.0000000000000016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Bestavashvili A, Glazachev O, Bestavashvili A, Suvorov A, Zhang Y, Zhang X, Rozhkov A, Kuznetsova N, Pavlov C, Glushenkov D, Kopylov P. Intermittent Hypoxic-Hyperoxic Exposures Effects in Patients with Metabolic Syndrome: Correction of Cardiovascular and Metabolic Profile. Biomedicines 2022;10:566. [PMID: 35327372 DOI: 10.3390/biomedicines10030566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Li T, Gong H, Zhan B, Mao X. Chitosan oligosaccharide attenuates hepatic steatosis in HepG2 cells via the activation of AMP‐activated protein kinase. Journal of Food Biochemistry. [DOI: 10.1111/jfbc.14045] [Reference Citation Analysis]
30 Xing Y, Chen J, Liu J, Ma H. Associations Between GGT/HDL and MAFLD: A Cross-Sectional Study. Diabetes Metab Syndr Obes 2022;15:383-94. [PMID: 35177915 DOI: 10.2147/DMSO.S342505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Smirne C, Croce E, Di Benedetto D, Cantaluppi V, Comi C, Sainaghi PP, Minisini R, Grossini E, Pirisi M. Oxidative Stress in Non-Alcoholic Fatty Liver Disease. Livers 2022;2:30-76. [DOI: 10.3390/livers2010003] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
32 Spoletini G, Ferri F, Mauro A, Mennini G, Bianco G, Cardinale V, Agnes S, Rossi M, Avolio AW, Lai Q. CONUT Score Predicts Early Morbidity After Liver Transplantation: A Collaborative Study. Front Nutr 2021;8:793885. [PMID: 35071299 DOI: 10.3389/fnut.2021.793885] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Zou J, Xiong H, Zhang H, Hu C, Lu S, Zou Y. Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02099-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Fan K, Yang X, Zhou C, Mei X, Yang X, Fu Q, Li Y, Lin Y, Yang C. Optimization of the extraction process of polyphenols from Allium cepa using response surface methodology and assessment of its antioxidant and lipid-lowering action. Food Measure. [DOI: 10.1007/s11694-021-01239-4] [Reference Citation Analysis]
35 Katsiki N, Athyros V. Serum uric acid: a mediator of cardio-reno-metabolic diseases. Expert Rev Cardiovasc Ther 2021;:1-2. [PMID: 34931915 DOI: 10.1080/14779072.2021.2021071] [Reference Citation Analysis]
36 Wang J, Su Z, Feng Y, Xi R, Liu J, Wang P. Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China. BMC Gastroenterol 2021;21:482. [PMID: 34923965 DOI: 10.1186/s12876-021-02072-1] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
37 Daradics Z, Crecan CM, Rus MA, Morar IA, Mircean MV, Cătoi AF, Cecan AD, Cătoi C. Obesity-Related Metabolic Dysfunction in Dairy Cows and Horses: Comparison to Human Metabolic Syndrome. Life 2021;11:1406. [DOI: 10.3390/life11121406] [Reference Citation Analysis]
38 Zhang Y, Yang L, Zhao N, Hong Z, Cai B, Le Q, Yang T, Shi L, He J. Soluble Polysaccharide Derived from Laminaria japonica Attenuates Obesity-Related Nonalcoholic Fatty Liver Disease Associated with Gut Microbiota Regulation. Mar Drugs 2021;19:699. [PMID: 34940698 DOI: 10.3390/md19120699] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
39 Hu X, Yu W, Yang L, Pan W, Xu K, Chen X, Li Q, Zhang Y, Chen G, Wen J, Gu X, Zhang X. First-degree family history of diabetes is associated with nonalcoholic fatty liver disease independent of glucose metabolic status. J Diabetes Complications 2022;36:108083. [PMID: 34840086 DOI: 10.1016/j.jdiacomp.2021.108083] [Reference Citation Analysis]
40 Kwak JH, Lee HJ, Jeong ST, Lee JY, Lee M, Paik JK. Effect of fermented Rhus verniciflua stokes extract on liver function parameters in healthy Korean adults: a double-blind randomized controlled trial. Trials 2021;22:830. [PMID: 34809689 DOI: 10.1186/s13063-021-05656-0] [Reference Citation Analysis]
41 Fling RR, Zacharewski TR. Aryl Hydrocarbon Receptor (AhR) Activation by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) Dose-Dependently Shifts the Gut Microbiome Consistent with the Progression of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:12431. [PMID: 34830313 DOI: 10.3390/ijms222212431] [Reference Citation Analysis]
42 Liu S, Weng R, Gu X, Li L, Zhong Z. Association between apolipoprotein E gene polymorphism and nonalcoholic fatty liver disease in Southern China: A case-control study. J Clin Lab Anal 2021;:e24061. [PMID: 34664321 DOI: 10.1002/jcla.24061] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
43 Zou Y, Lan J, Zhong Y, Yang S, Zhang H, Xie G. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. Lipids Health Dis 2021;20:139. [PMID: 34657611 DOI: 10.1186/s12944-021-01573-y] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
44 Hu MJ, Long M, Dai RJ. Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3. Mol Cell Biochem 2021. [PMID: 34652536 DOI: 10.1007/s11010-021-04269-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Li F, Liu G, Xue P, Ren Z, Dai P, Niu W, Xin M. YiQi YangYin Decoction Attenuates Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Rats. Evid Based Complement Alternat Med 2021;2021:5511019. [PMID: 34621322 DOI: 10.1155/2021/5511019] [Reference Citation Analysis]
46 Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology 2021;74:1809-24. [PMID: 33811367 DOI: 10.1002/hep.31843] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 39.0] [Reference Citation Analysis]
47 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
48 Lee JH, Lee HS, Ahn SB, Kwon YJ. Dairy protein intake is inversely related to development of non-alcoholic fatty liver disease. Clin Nutr 2021;40:5252-60. [PMID: 34534894 DOI: 10.1016/j.clnu.2021.08.012] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
49 Aguiar AJFC, de Queiroz JLC, Santos PPA, Camillo CS, Serquiz AC, Costa IS, Oliveira GS, Gomes AFT, Matias LLR, Costa ROA, Passos TS, Morais AHA. Beneficial Effects of Tamarind Trypsin Inhibitor in Chitosan-Whey Protein Nanoparticles on Hepatic Injury Induced High Glycemic Index Diet: A Preclinical Study. Int J Mol Sci 2021;22:9968. [PMID: 34576130 DOI: 10.3390/ijms22189968] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Chen LJ, Guo J, Zhang SX, Xu Y, Zhao Q, Zhang W, Xiao J, Chen Y. Sirtuin3 rs28365927 functional variant confers to the high risk of non-alcoholic fatty liver disease in Chinese Han population. Lipids Health Dis 2021;20:92. [PMID: 34446002 DOI: 10.1186/s12944-021-01520-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Malik A, Nadeem M, Malik MI. Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis. Clin J Gastroenterol 2021. [PMID: 34370218 DOI: 10.1007/s12328-021-01491-7] [Reference Citation Analysis]
52 Yoshimura Y, Hamaguchi M, Hashimoto Y, Okamura T, Nakanishi N, Obora A, Kojima T, Fukui M. Obesity and metabolic abnormalities as risks of alcoholic fatty liver in men: NAGALA study. BMC Gastroenterol 2021;21:321. [PMID: 34372774 DOI: 10.1186/s12876-021-01893-4] [Reference Citation Analysis]
53 Lee MCM, Kachura JJ, Vlachou PA, Dzulynsky R, Di Tomaso A, Samawi H, Baxter N, Brezden-Masley C. Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer. Curr Oncol 2021;28:3030-40. [PMID: 34436031 DOI: 10.3390/curroncol28040265] [Reference Citation Analysis]
54 Wu Y, Johnson G, Zhao F, Wu Y, Zhao G, Brown A, You S, Zou MH, Song P. Features of Lipid Metabolism in Humanized ApoE Knockin Rat Models. Int J Mol Sci 2021;22:8262. [PMID: 34361033 DOI: 10.3390/ijms22158262] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
56 Templehof H, Moshe N, Avraham-Davidi I, Yaniv K. Zebrafish mutants provide insights into Apolipoprotein B functions during embryonic development and pathological conditions. JCI Insight 2021;6:130399. [PMID: 34236046 DOI: 10.1172/jci.insight.130399] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
57 Zhao W, An R, Liu F, Gu J, Sun Y, Xu S, Pan Y, Gao Z, Ji H, Du Z. Urinary metabolomics analysis of the protective effects of Daming capsule on hyperlipidemia rats using ultra-high-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. J Sep Sci 2021;44:3305-18. [PMID: 34185383 DOI: 10.1002/jssc.202100113] [Reference Citation Analysis]
58 Ji L, Cai X, Bai Y, Li T. Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China. Int J Gen Med 2021;14:2909-22. [PMID: 34234521 DOI: 10.2147/IJGM.S319759] [Reference Citation Analysis]
59 Johnston MP, Patel J, Byrne CD. Update on cardiovascular risk in nonalcoholic fatty liver disease. Curr Opin Cardiol 2021;36:478-86. [PMID: 34059612 DOI: 10.1097/HCO.0000000000000861] [Reference Citation Analysis]
60 Katsiki N, Doumas M. Emerging Cardiovascular Risk Factors and Specific Patient Populations at Increased Cardiovascular Risk. Curr Vasc Pharmacol 2021;19:241-2. [PMID: 33413053 DOI: 10.2174/157016111903201231115755] [Reference Citation Analysis]
61 Saito H, Tanabe H, Kudo A, Machii N, Higa M, Yamaguchi S, Maimaituxun G, Abe K, Takahashi A, Tanaka K, Asahi K, Masuzaki H, Ohira H, Kazama JJ, Shimabukuro M. High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. Sci Rep 2021;11:11753. [PMID: 34083571 DOI: 10.1038/s41598-021-88285-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 El-sayed W, Alkabli J, Aloqbi A, Elshaarawy RF. Optimization enzymatic degradation of chitosan into amphiphilic chitooligosaccharides for application in mitigating liver steatosis and cholesterol regulation. European Polymer Journal 2021;153:110507. [DOI: 10.1016/j.eurpolymj.2021.110507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
63 Appannah G, Emi NA, Magendiran M, Mohd Shariff Z, Anuar Zaini A, Shamsuddin NH, Suppiah S, Mohamad Saini S, Thambiah SC, Ching SM. PUTRA-Adol study: protocol for an observational follow-up study to assess the tracking of dietary patterns linked to cardiometabolic risk factors and its prospective relationship with non-alcoholic fatty liver disease, carotid intima-medial thickness and mental well-being during adolescence in Malaysia. BMJ Open 2021;11:e044747. [PMID: 34035098 DOI: 10.1136/bmjopen-2020-044747] [Reference Citation Analysis]
64 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]
65 Xu L, Wang K, Wang S, Liu L, Lv X, Song Y. Sex differences in the association between serum lipids and depressive symptoms: A longitudinal population-based study. J Affect Disord 2021;291:154-62. [PMID: 34038832 DOI: 10.1016/j.jad.2021.05.011] [Reference Citation Analysis]
66 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 60] [Cited by in F6Publishing: 72] [Article Influence: 60.0] [Reference Citation Analysis]
67 Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. Cardiovasc Diabetol 2021;20:96. [PMID: 33947390 DOI: 10.1186/s12933-021-01291-w] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
68 Yang Y, Wei J, Li J, Cui Y, Zhou X, Xie J. Lipid metabolism in cartilage and its diseases: a concise review of the research progress. Acta Biochim Biophys Sin (Shanghai) 2021;53:517-27. [PMID: 33638344 DOI: 10.1093/abbs/gmab021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
69 Imprialos KP, Stavropoulos K, Doumas M, Athyros VG. The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease. Angiology 2021;:33197211005597. [PMID: 33827290 DOI: 10.1177/00033197211005597] [Reference Citation Analysis]
70 Wasilewska N, Lebensztejn DM. Non-alcoholic fatty liver disease and lipotoxicity. Clin Exp Hepatol 2021;7:1-6. [PMID: 34027109 DOI: 10.5114/ceh.2021.104441] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
71 Flisiak-Jackiewicz M, Bobrus-Chociej A, Wasilewska N, Lebensztejn DM. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction? J Clin Med 2021;10:924. [PMID: 33804296 DOI: 10.3390/jcm10050924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
72 Li HY, Gan RY, Shang A, Mao QQ, Sun QC, Wu DT, Geng F, He XQ, Li HB. Plant-Based Foods and Their Bioactive Compounds on Fatty Liver Disease: Effects, Mechanisms, and Clinical Application. Oxid Med Cell Longev 2021;2021:6621644. [PMID: 33728021 DOI: 10.1155/2021/6621644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
73 Garduno A, Wu T. Tobacco Smoke and CYP1A2 Activity in a US Population with Normal Liver Enzyme Levels. Int J Environ Res Public Health 2021;18:2225. [PMID: 33668222 DOI: 10.3390/ijerph18052225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Heo YJ, Choi SE, Lee N, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW, Kim HJ. Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model. J Gastroenterol Hepatol 2021. [PMID: 33600604 DOI: 10.1111/jgh.15465] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Wang Y, Guo P, Liu L, Zhang Y, Zeng P, Yuan Z. Mendelian Randomization Highlights the Causal Role of Normal Thyroid Function on Blood Lipid Profiles. Endocrinology 2021;162:bqab037. [PMID: 33587120 DOI: 10.1210/endocr/bqab037] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
76 Tao S, Yang Y, Li J, Wang H, Ma Y. Bixin Attenuates High-Fat Diet-Caused Liver Steatosis and Inflammatory Injury through Nrf2/PPARα Signals. Oxid Med Cell Longev 2021;2021:6610124. [PMID: 33603948 DOI: 10.1155/2021/6610124] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
77 Li Y, Liu Y, Yang M, Wang Q, Zheng Y, Xu J, Zheng P, Song H. A Study on the Therapeutic Efficacy of San Zi Yang Qin Decoction for Non-Alcoholic Fatty Liver Disease and the Underlying Mechanism Based on Network Pharmacology. Evid Based Complement Alternat Med 2021;2021:8819245. [PMID: 33505505 DOI: 10.1155/2021/8819245] [Reference Citation Analysis]
78 Guo W, Wu D, Dao MC, Li L, Lewis ED, Ortega EF, Eom H, Thomas M, Nikolova-Karakashian M, Meydani M, Meydani SN. A Novel Combination of Fruits and Vegetables Prevents Diet-Induced Hepatic Steatosis and Metabolic Dysfunction in Mice. J Nutr 2020;150:2950-60. [PMID: 32939550 DOI: 10.1093/jn/nxaa259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Yang D, Zhang X, Yue L, Hu H, Wei X, Guo Q, Zhang B, Fan X, Xin Y, Oh Y, Gu N. Thiamethoxam induces nonalcoholic fatty liver disease in mice via methionine metabolism disturb via nicotinamide N-methyltransferase overexpression. Chemosphere 2021;273:129727. [PMID: 33524747 DOI: 10.1016/j.chemosphere.2021.129727] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
80 Filippatos TD, Alexakis K, Mavrikaki V, Mikhailidis DP. Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis. Dig Dis Sci 2021. [PMID: 33469809 DOI: 10.1007/s10620-021-06824-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
81 Mangrulkar S, Shah P, Navnage S, Mazumdar P, Chaple D. Phytophospholipid Complex of Caffeic Acid: Development, In vitro Characterization, and In Vivo Investigation of Antihyperlipidemic and Hepatoprotective Action in Rats. AAPS PharmSciTech 2021;22:28. [PMID: 33404939 DOI: 10.1208/s12249-020-01887-7] [Reference Citation Analysis]
82 Rosqvist F, Rydell A, Iggman D. The Effects of Foods on Blood Lipids in Non-alcoholic Fatty Liver Disease (NAFLD)-A Systematic Review and Meta-Analysis. Front Nutr 2020;7:613221. [PMID: 33392241 DOI: 10.3389/fnut.2020.613221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
84 Su W, Wang Y, Chen K, Wang J, Wang A, Tang X, Yan L, Luo Z, Qin G, Chen L, Ning G, Mu Y. Association between nonalcoholic fatty liver and increased low-level albuminuria in postmenopausal women in China: A cross-sectional study. J Diabetes 2021;13:494-505. [PMID: 33200507 DOI: 10.1111/1753-0407.13134] [Reference Citation Analysis]
85 Yu G, Yang Z, Peng T, Lv Y. Circular RNAs: Rising stars in lipid metabolism and lipid disorders. J Cell Physiol 2021;236:4797-806. [PMID: 33275299 DOI: 10.1002/jcp.30200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
86 Choi CJ, Weiss SH, Nasir UM, Pyrsopoulos NT. Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis. World J Hepatol 2020;12:993-1003. [PMID: 33312424 DOI: 10.4254/wjh.v12.i11.993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
87 Yang S, Zhong J, Ye M, Miao L, Lu G, Xu C, Xue Z, Zhou X. Association between the non-HDL-cholesterol to HDL-cholesterol ratio and non-alcoholic fatty liver disease in Chinese children and adolescents: a large single-center cross-sectional study. Lipids Health Dis 2020;19:242. [PMID: 33222696 DOI: 10.1186/s12944-020-01421-5] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
88 Katsiki N, Stoian AP, Steiropoulos P, Papanas N, Suceveanu AI, Mikhailidis DP. Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview. Metabolites 2020;10:E465. [PMID: 33203192 DOI: 10.3390/metabo10110465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
89 Cai X, Aierken X, Ahmat A, Cao Y, Zhu Q, Wu T, Li N. A Nomogram Model Based on Noninvasive Bioindicators to Predict 3-Year Risk of Nonalcoholic Fatty Liver in Nonobese Mainland Chinese: A Prospective Cohort Study. Biomed Res Int 2020;2020:8852198. [PMID: 33204721 DOI: 10.1155/2020/8852198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
90 Gonzalez-Aldaco K, Roman S, Torres-Reyes LA, Panduro A. Association of Apolipoprotein e2 Allele with Insulin Resistance and Risk of Type 2 Diabetes Mellitus Among an Admixed Population of Mexico. Diabetes Metab Syndr Obes 2020;13:3527-34. [PMID: 33116704 DOI: 10.2147/DMSO.S268329] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
91 Wang X, Zhang Z, Wu SC. Health Benefits of Silybum marianum: Phytochemistry, Pharmacology, and Applications. J Agric Food Chem 2020;68:11644-64. [PMID: 33045827 DOI: 10.1021/acs.jafc.0c04791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
92 Shao SY, Wang YL, Feng LM, Zhao Y. Serum non-high-density lipoprotein cholesterol level is increased in Chinese patients with nonalcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2020;19:602-4. [PMID: 33077366 DOI: 10.1016/j.hbpd.2020.09.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Katsiki N, Mantzoros C. Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated steatohepatitis). Metabolism 2021;114:154333. [PMID: 32771359 DOI: 10.1016/j.metabol.2020.154333] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Hwang HW, Yu JH, Jin YJ, Suh YJ, Lee JW. Correlation between the small dense LDL level and nonalcoholic fatty liver disease: Possibility of a new biomarker. Medicine (Baltimore) 2020;99:e21162. [PMID: 32664153 DOI: 10.1097/MD.0000000000021162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism 2020;111S:154318. [PMID: 32707055 DOI: 10.1016/j.metabol.2020.154318] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
96 Cremonini E, Iglesias DE, Kang J, Lombardo GE, Mostofinejad Z, Wang Z, Zhu W, Oteiza PI. (-)-Epicatechin and the comorbidities of obesity. Arch Biochem Biophys 2020;690:108505. [PMID: 32679195 DOI: 10.1016/j.abb.2020.108505] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
97 Sakasai-Sakai A, Takata T, Takeuchi M. Intracellular Toxic Advanced Glycation End-Products Promote the Production of Reactive Oxygen Species in HepG2 Cells. Int J Mol Sci 2020;21:E4861. [PMID: 32660150 DOI: 10.3390/ijms21144861] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
98 Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020;9:E1638. [PMID: 32650421 DOI: 10.3390/cells9071638] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
99 Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;52:619-36. [PMID: 32638417 DOI: 10.1111/apt.15935] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
100 Venetsanaki V, Polyzos SA. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. Curr Vasc Pharmacol. 2019;17:546-555. [PMID: 29992886 DOI: 10.2174/1570161116666180711121949] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
101 Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019;20:461-472. [PMID: 31707624 DOI: 10.1007/s11154-019-09512-0] [Cited by in Crossref: 228] [Cited by in F6Publishing: 225] [Article Influence: 114.0] [Reference Citation Analysis]
102 Katsiki N, Ferrannini E, Mantzoros C. New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. Metabolism 2020;107:154218. [DOI: 10.1016/j.metabol.2020.154218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
103 Bourrie BCT, Richard C, Willing BP. Kefir in the Prevention and Treatment of Obesity and Metabolic Disorders. Curr Nutr Rep 2020;9:184-92. [DOI: 10.1007/s13668-020-00315-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
104 Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Curr Vasc Pharmacol 2019;17:498-514. [PMID: 31060488 DOI: 10.2174/1570161117666190507110519] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
105 Doumas M, Imprialos K, Stavropoulos K, Athyros VG. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis? Curr Vasc Pharmacol 2019;17:425-8. [PMID: 31418344 DOI: 10.2174/157016111705190703102816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
106 Lin J, Zheng J, Lin X, Chen Y, Li Z. A Low Creatinine to Body Weight Ratio Predicts the Incident Nonalcoholic Fatty Liver Disease in Nonelderly Chinese without Obesity and Dyslipidemia: A Retrospective Study. Gastroenterol Res Pract 2020;2020:4043871. [PMID: 32454814 DOI: 10.1155/2020/4043871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
107 Muniz LB, Alves-Santos AM, Camargo F, Martins DB, Celes MRN, Naves MMV. High-Lard and High-Cholesterol Diet, but not High-Lard Diet, Leads to Metabolic Disorders in a Modified Dyslipidemia Model. Arq Bras Cardiol 2019;113:896-902. [PMID: 31482944 DOI: 10.5935/abc.20190149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
108 Tutunchi H, Saghafi-Asl M, Asghari-Jafarabadi M, Ostadrahimi A. The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults. BMC Res Notes 2020;13:218. [PMID: 32299490 DOI: 10.1186/s13104-020-05059-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
109 Shoieb SM, El-ghiaty MA, Alqahtani MA, El-kadi AO. Cytochrome P450-derived eicosanoids and inflammation in liver diseases. Prostaglandins & Other Lipid Mediators 2020;147:106400. [DOI: 10.1016/j.prostaglandins.2019.106400] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
110 Chen S, Yang H, Chen Y, Wang J, Xu L, Miao M, Xu C. Association between serum uric acid levels and dyslipidemia in Chinese adults: A cross-sectional study and further meta-analysis. Medicine (Baltimore) 2020;99:e19088. [PMID: 32176036 DOI: 10.1097/MD.0000000000019088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
111 Wu H, Ni X, Xu Q, Wang Q, Li X, Hua J. Regulation of lipid‐induced macrophage polarization through modulating peroxisome proliferator‐activated receptor‐gamma activity affects hepatic lipid metabolism via a Toll‐like receptor 4/NF‐κB signaling pathway. Journal of Gastroenterology and Hepatology 2020;35:1998-2008. [DOI: 10.1111/jgh.15025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
112 Katsiki N, Anagnostis P, Kotsa K, Goulis DG, Mikhailidis DP. Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. Curr Pharm Des. 2019;25:2051-2059. [PMID: 31298151 DOI: 10.2174/1381612825666190708192134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
113 Polyzos SA, Kountouras J, Mantzoros CS. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. Metabolism 2020;104:154144. [DOI: 10.1016/j.metabol.2020.154144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
114 Dai L, Feng Z, Zha R, Cheng K, Wen X, Sun H, Yuan H. Discovery of Novel Peroxisome Proliferator-Activated Receptor α (PPARα) Agonists by Virtual Screening and Biological Evaluation. J Chem Inf Model 2020;60:1717-27. [DOI: 10.1021/acs.jcim.9b00838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
115 Katsiki N, Tousoulis D. Diabetes mellitus and comorbidities: A bad romance. Hellenic Journal of Cardiology 2020;61:23-5. [DOI: 10.1016/j.hjc.2020.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Lee WD, Kim BK, Park JY, Kim DY, Ahn SH, Han K, Kim SU. Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. European Journal of Gastroenterology & Hepatology 2020;32:1538-44. [DOI: 10.1097/meg.0000000000001665] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
117 Milošević N, Milanović M, Sudji J, Bosić Živanović D, Stojanoski S, Vuković B, Milić N, Medić Stojanoska M. Could phthalates exposure contribute to the development of metabolic syndrome and liver disease in humans? Environ Sci Pollut Res Int 2020;27:772-84. [PMID: 31808097 DOI: 10.1007/s11356-019-06831-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
118 Katsiki N, Gastaldelli A, Mikhailidis DP. Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A “non-invasive alternative” to liver biopsy? Metabolism 2019;101:154010. [DOI: 10.1016/j.metabol.2019.154010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
119 Tucker B, Li H, Long X, Rye K, Ong KL. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism 2019;101:153994. [DOI: 10.1016/j.metabol.2019.153994] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 14.3] [Reference Citation Analysis]
120 Lv Y, Patel N, Zhang HJ. The progress of non-alcoholic fatty liver disease as the risk of liver metastasis in colorectal cancer. Expert Rev Gastroenterol Hepatol 2019;13:1169-80. [PMID: 31774328 DOI: 10.1080/17474124.2019.1697231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
121 Ma X, Jiang S, Yan S, Li M, Wang C, Pan Y, Sun C, Jin L, Yao Y, Li B. Association Between Copper, Zinc, Iron, and Selenium Intakes and TC/HDL-C Ratio in US Adults. Biol Trace Elem Res 2020;197:43-51. [DOI: 10.1007/s12011-019-01979-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
122 Astbury S, Atallah E, Vijay A, Aithal GP, Grove JI, Valdes AM. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes 2020;11:569-80. [PMID: 31696774 DOI: 10.1080/19490976.2019.1681861] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 17.7] [Reference Citation Analysis]
123 Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Metabolism 2019;101:154001. [PMID: 31672448 DOI: 10.1016/j.metabol.2019.154001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
124 Bekyarova G, Tzaneva M, Bratoeva K, Ivanova I, Kotzev A, Hristova M, Krastev D, Kindekov I, Mileva M. 4-Hydroxynonenal (HNE) and hepatic injury related to chronic oxidative stress. Biotechnology & Biotechnological Equipment 2019;33:1544-52. [DOI: 10.1080/13102818.2019.1674690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
125 Han JM, Kim HI, Lee YJ, Lee JW, Kim KM, Bae JC. Differing Associations between Fatty Liver and Dyslipidemia According to the Degree of Hepatic Steatosis in Korea. J Lipid Atheroscler 2019;8:258-66. [PMID: 32821716 DOI: 10.12997/jla.2019.8.2.258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
126 Venetsanaki V, Karabouta Z, Polyzos SA. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. Eur J Pharmacol. 2019;863:172661. [PMID: 31536725 DOI: 10.1016/j.ejphar.2019.172661] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
127 Katsiki N, Mikhailidis DP, Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opinion on Pharmacotherapy 2019;20:2007-17. [DOI: 10.1080/14656566.2019.1649394] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
128 Kolovou GD, Watts GF, Mikhailidis DP, Pérez-martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-miranda J, Tybjærg-hansen A, Tentolouris N, Nordestgaard BG. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. CVP 2019;17:515-37. [DOI: 10.2174/1570161117666190503123911] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
129 Mazidi M, Katsiki N, Mikhailidis DP, Banach M. Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. J Am Coll Nutr 2019;38:633-9. [PMID: 31305223 DOI: 10.1080/07315724.2018.1507011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
130 Katsiki N, Perakakis N, Mantzoros C. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus? Metabolism 2019;98:iii-ix. [PMID: 31301336 DOI: 10.1016/j.metabol.2019.07.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
131 Qian M, Lyu Q, Liu Y, Hu H, Wang S, Pan C, Duan X, Gao Y, Qi LW, Liu W, Wang L. Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice. Mar Drugs 2019;17:E391. [PMID: 31269758 DOI: 10.3390/md17070391] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
132 Jeong SM, Kwon H, Park S, Yu SJ, Jeong HY, Nam KW, Kwon HM, Park JH. Favorable impact of non-alcoholic fatty liver disease on the cerebral white matter hyperintensity in a neurologically healthy population. Eur J Neurol 2019;26:1471-8. [PMID: 31233672 DOI: 10.1111/ene.14029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
133 Roth JD, Veidal SS, Fensholdt LKD, Rigbolt KTG, Papazyan R, Nielsen JC, Feigh M, Vrang N, Young M, Jelsing J, Adorini L, Hansen HH. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Sci Rep 2019;9:9046. [PMID: 31227742 DOI: 10.1038/s41598-019-45178-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
134 Park S, Zhang T, Qiu JY, Wu X. The Combination of Mulberry Extracts and Silk Amino Acids Alleviated High Fat Diet-Induced Nonalcoholic Hepatic Steatosis by Improving Hepatic Insulin Signaling and Normalizing Gut Microbiome Dysbiosis in Rats. Evid Based Complement Alternat Med 2019;2019:8063121. [PMID: 31275421 DOI: 10.1155/2019/8063121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
135 Katsiki N, Dimitriadis G, Mikhailidis DP. Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection? Angiology 2018;70:581-3. [DOI: 10.1177/0003319719848204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
136 Polyzos SA, Perakakis N, Mantzoros CS. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism 2019;96:66-82. [PMID: 31071311 DOI: 10.1016/j.metabol.2019.05.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 16.3] [Reference Citation Analysis]
137 El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;20:E2215. [PMID: 31064058 DOI: 10.3390/ijms20092215] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
138 Zhang S, Xie L, Yu H, Zhang W, Qian B. Association between nighttime-daytime sleep patterns and chronic diseases in Chinese elderly population: a community-based cross-sectional study. BMC Geriatr 2019;19:124. [PMID: 31035939 DOI: 10.1186/s12877-019-1136-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
139 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 73] [Article Influence: 17.0] [Reference Citation Analysis]
140 Katsiki N, Dimitriadis G, Hahalis G, Papanas N, Tentolouris N, Triposkiadis F, Tsimihodimos V, Tsioufis C, Mikhailidis DP, Mantzoros C. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. Metabolism. 2019;96:92-100. [PMID: 30980838 DOI: 10.1016/j.metabol.2019.04.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
141 Jeong MJ, Kim SR, Jung UJ. Schizandrin A supplementation improves nonalcoholic fatty liver disease in mice fed a high-fat and high-cholesterol diet. Nutrition Research 2019;64:64-71. [DOI: 10.1016/j.nutres.2019.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
142 Katsiki N, Athyros VG. Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. Curr Med Res Opin 2019;35:1305-6. [PMID: 30819009 DOI: 10.1080/03007995.2019.1589152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obesity Reviews 2019;20:805-15. [DOI: 10.1111/obr.12839] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
144 Li Y, Liu S, Gao Y, Ma H, Zhan S, Yang Y, Xin Y, Xuan S. Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population. BMC Biochem 2019;20:3. [PMID: 30727943 DOI: 10.1186/s12858-019-0106-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
145 Katsiki N, Mantzoros C. Fibroblast growth factor 21: A role in cardiometabolic disorders and cardiovascular risk prediction? Metabolism 2019;93:iii-v. [PMID: 30659799 DOI: 10.1016/j.metabol.2019.01.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
146 Guo Y, Ding PH, Liu LJ, Shi L, Mao TY, Li JX, Wang YL. Gegen Qinlian Decoction Attenuates High-Fat Diet-Induced Steatohepatitis in Rats via Gut Microbiota. Evid Based Complement Alternat Med 2018;2018:7370891. [PMID: 30671129 DOI: 10.1155/2018/7370891] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
147 Almanza D, Gharaee-Kermani M, Zhilin-Roth A, Rodriguez-Nieves JA, Colaneri C, Riley T, Macoska JA. Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature. Dig Dis Sci 2019;64:1257-69. [PMID: 30519850 DOI: 10.1007/s10620-018-5398-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
148 Zheng R, Du Z, Wang M, Mao Y, Mao W. A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease. Lipids Health Dis 2018;17:262. [PMID: 30458848 DOI: 10.1186/s12944-018-0913-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
149 Dattilo G, Borgia F, Guarneri C, Casale M, Bitto R, Morabito C, Signorelli S, Katsiki N, Cannavò SP. Cardiovascular Risk in Psoriasis: Current State of the Art. CVP 2018;17:85-91. [DOI: 10.2174/1570161115666171116163816] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
150 Mazidi M, Katsiki N, Mikhailidis DP, Banach M. Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey. Atherosclerosis 2019;284:129-35. [PMID: 30878840 DOI: 10.1016/j.atherosclerosis.2018.11.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
151 Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism 2019;92:98-107. [PMID: 30399375 DOI: 10.1016/j.metabol.2018.10.011] [Cited by in Crossref: 212] [Cited by in F6Publishing: 174] [Article Influence: 53.0] [Reference Citation Analysis]
152 Wargny M, Ducluzeau P, Petit J, Le May C, Smati S, Arnaud L, Pichelin M, Bouillet B, Lannes A, Blanchet O, Lefebvre P, Francque S, Van Gaal L, Staels B, Vergès B, Boursier J, Cariou B. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. Atherosclerosis 2018;278:82-90. [DOI: 10.1016/j.atherosclerosis.2018.09.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
153 Narayanankutty A, Anil A, Illam SP, Kandiyil SP, Raghavamenon AC. Non-polar lipid carbonyls of thermally oxidized coconut oil induce hepatotoxicity mediated by redox imbalance. Prostaglandins, Leukotrienes and Essential Fatty Acids 2018;138:45-51. [DOI: 10.1016/j.plefa.2018.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
154 Song HS, Koo HJ, Park BK, Kwon JE, Jang SA, Baek HJ, Kim SY, Lee SR, Kang SC. The suppressive effect of the three-herb extract mixture on vascular and liver inflammation in atherogenic diet with high fructose-fed mice. Pharm Biol 2018;56:32-42. [PMID: 29772938 DOI: 10.1080/13880209.2017.1412468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
155 Okopień B, Bułdak Ł, Bołdys A. Benefits and risks of the treatment with fibrates––a comprehensive summary. Expert Review of Clinical Pharmacology 2018;11:1099-112. [DOI: 10.1080/17512433.2018.1537780] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
156 Domínguez-avila JA, Astiazaran-garcia H, Wall-medrano A, de la Rosa LA, Alvarez-parrilla E, González-aguilar GA. Mango phenolics increase the serum apolipoprotein A1/B ratio in rats fed high cholesterol and sodium cholate diets: Effects of mango phenolics on apolipoproteins of rats fed high sterol diets. J Sci Food Agric 2019;99:1604-12. [DOI: 10.1002/jsfa.9340] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
157 Reis MÁ, Novaes RD, Baggio SR, Viana ALM, Salles BCC, Duarte SMDS, Rodrigues MR, Paula FBA. Hepatoprotective and Antioxidant Activities of Oil from Baru Almonds (Dipteryx alata Vog.) in a Preclinical Model of Lipotoxicity and Dyslipidemia. Evid Based Complement Alternat Med 2018;2018:8376081. [PMID: 30369957 DOI: 10.1155/2018/8376081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
158 Katsiki N, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease and colorectal cancer: A marker of risk or common causation? Metabolism 2018;87:A10-3. [DOI: 10.1016/j.metabol.2018.08.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
159 Lu YW, Zhu YC, Zhang L, Li P, Yang J, Wen XD. Ilexgenin A enhances the effects of simvastatin on non-alcoholic fatty liver disease without changes in simvastatin pharmacokinetics. Chin J Nat Med 2018;16:436-45. [PMID: 30047465 DOI: 10.1016/S1875-5364(18)30077-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
160 Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. Clin Diabetes. 2019;37:65-72. [PMID: 30705499 DOI: 10.2337/cd18-0026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 42] [Article Influence: 7.5] [Reference Citation Analysis]
161 Kurniawan DW, Jajoriya AK, Dhawan G, Mishra D, Argemi J, Bataller R, Storm G, Mishra DP, Prakash J, Bansal R. Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis. J Control Release. 2018;288:227-238. [PMID: 30219279 DOI: 10.1016/j.jconrel.2018.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
162 Cho YK, Kang YM, Yoo JH, Lee J, Lee SE, Yang DH, Kang JW, Park JY, Jung CH, Kim HK, Lee WJ. The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification. Sci Rep 2018;8:12004. [PMID: 30104707 DOI: 10.1038/s41598-018-30465-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
163 Taher J, Baker C, Alvares D, Ijaz L, Hussain M, Adeli K. GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice. Endocrinology 2018;159:3340-50. [DOI: 10.1210/en.2018-00416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
164 Miyakoshi T, Sagesaka H, Sato Y, Hirbayashi K, Koike H, Yamashita K, Usuda S, Kiyosawa K, Shimodaira M, Aizawa T. Reappraisal of attenuated insulin sensitivity in the evolution of non-alcoholic fatty liver disease. Eur J Clin Nutr 2019;73:770-5. [PMID: 30018458 DOI: 10.1038/s41430-018-0246-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
165 Liu Z, Li H, Zheng Y, Gao Z, Cong L, Yang L, Zhou Y. Association of Lipoprotein-Associated Phospholipase A2 with the Prevalence of Nonalcoholic Fatty Liver Disease: A Result from the APAC Study. Sci Rep. 2018;8:10127. [PMID: 29973631 DOI: 10.1038/s41598-018-28494-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
166 Yaribeygi H, Katsiki N, Behnam B, Iranpanah H, Sahebkar A. MicroRNAs and type 2 diabetes mellitus: Molecular mechanisms and the effect of antidiabetic drug treatment. Metabolism. 2018;87:48-55. [PMID: 30253864 DOI: 10.1016/j.metabol.2018.07.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
167 Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin 2018;39:1176-88. [PMID: 29877321 DOI: 10.1038/aps.2018.40] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 27.0] [Reference Citation Analysis]
168 Panchal SK, Bliss E, Brown L. Capsaicin in Metabolic Syndrome. Nutrients 2018;10:E630. [PMID: 29772784 DOI: 10.3390/nu10050630] [Cited by in Crossref: 37] [Cited by in F6Publishing: 47] [Article Influence: 9.3] [Reference Citation Analysis]
169 Wang GE, Li YF, Zhai YJ, Gong L, Tian JY, Hong M, Yao N, Wu YP, Kurihara H, He RR. Theacrine protects against nonalcoholic fatty liver disease by regulating acylcarnitine metabolism. Metabolism 2018;85:227-39. [PMID: 29727630 DOI: 10.1016/j.metabol.2018.04.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
170 Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes Endocrinol 2017;5:329-30. [PMID: 28434490 DOI: 10.1016/S2213-8587(17)30109-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
171 Harlow KE, Africa JA, Wells A, Belt PH, Behling CA, Jain AK, Molleston JP, Newton KP, Rosenthal P, Vos MB, Xanthakos SA, Lavine JE, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. J Pediatr 2018;198:76-83.e2. [PMID: 29661561 DOI: 10.1016/j.jpeds.2018.02.038] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
172 Rosales-cruz P, Domínguez-pérez M, Reyes-zárate E, Bello-monroy O, Enríquez-cortina C, Miranda-labra R, Bucio L, Gómez-quiroz LE, Rojas-del Castillo E, Gutiérrez-ruíz MC, Souza-arroyo V. Cadmium exposure exacerbates hyperlipidemia in cholesterol-overloaded hepatocytes via autophagy dysregulation. Toxicology 2018;398-399:41-51. [DOI: 10.1016/j.tox.2018.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
173 Katsiki N, Giannoukas AD, Athyros VG, Mikhailidis DP. Lipid-lowering treatment in peripheral artery disease. Current Opinion in Pharmacology 2018;39:19-26. [DOI: 10.1016/j.coph.2018.01.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
174 Katsiki N, Mantzoros C, Mikhailidis DP. Adiponectin, lipids and atherosclerosis. Curr Opin Lipidol. 2017;28:347-354. [PMID: 28463859 DOI: 10.1097/mol.0000000000000431] [Cited by in Crossref: 69] [Cited by in F6Publishing: 46] [Article Influence: 17.3] [Reference Citation Analysis]
175 Chen Z, Xu YY, Wu R, Han YX, Yu Y, Ge JF, Chen FH. Impaired learning and memory in rats induced by a high-fat diet: Involvement with the imbalance of nesfatin-1 abundance and copine 6 expression. J Neuroendocrinol 2017;29. [PMID: 28211103 DOI: 10.1111/jne.12462] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
176 Morrison MC, Kleemann R, van Koppen A, Hanemaaijer R, Verschuren L. Key Inflammatory Processes in Human NASH Are Reflected in Ldlr-/-.Leiden Mice: A Translational Gene Profiling Study. Front Physiol 2018;9:132. [PMID: 29527177 DOI: 10.3389/fphys.2018.00132] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
177 Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 2018;12:331-9. [DOI: 10.1080/17474124.2018.1439379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
178 Li D, Liu J, Hua X, Fu H, Huang F, Fei Y, Lu W, Shen F, Wang P. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease. Metabolism 2018;79:52-63. [DOI: 10.1016/j.metabol.2017.11.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
179 Jensen VS, Hvid H, Damgaard J, Nygaard H, Ingvorsen C, Wulff EM, Lykkesfeldt J, Fledelius C. Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats. Diabetol Metab Syndr. 2018;10:4. [PMID: 29410708 DOI: 10.1186/s13098-018-0307-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
180 Katsiki N, Kolovou G, Perez-Martinez P, Mikhailidis DP. Dyslipidaemia in the elderly: to treat or not to treat? Expert Rev Clin Pharmacol 2018;11:259-78. [PMID: 29303009 DOI: 10.1080/17512433.2018.1425138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Kwon EB, Kang MJ, Kim SY, Lee YM, Lee MK, Yuk HJ, Ryu HW, Lee SU, Oh SR, Moon DO, Lee HS, Kim MO. Zanthoxylum ailanthoides Suppresses Oleic Acid-Induced Lipid Accumulation through an Activation of LKB1/AMPK Pathway in HepG2 Cells. Evid Based Complement Alternat Med 2018;2018:3140267. [PMID: 29507591 DOI: 10.1155/2018/3140267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
182 Boutari C, Perakakis N, Mantzoros CS. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul). 2018;33:33-43. [PMID: 29589386 DOI: 10.3803/enm.2018.33.1.33] [Cited by in Crossref: 61] [Cited by in F6Publishing: 80] [Article Influence: 15.3] [Reference Citation Analysis]
183 Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37 Suppl 1:97-103. [PMID: 28052626 DOI: 10.1111/liv.13302] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 21.4] [Reference Citation Analysis]
184 Coudriet GM, Delmastro-Greenwood MM, Previte DM, Marré ML, O'Connor EC, Novak EA, Vincent G, Mollen KP, Lee S, Dong HH, Piganelli JD. Treatment with a Catalytic Superoxide Dismutase (SOD) Mimetic Improves Liver Steatosis, Insulin Sensitivity, and Inflammation in Obesity-Induced Type 2 Diabetes. Antioxidants (Basel) 2017;6:E85. [PMID: 29104232 DOI: 10.3390/antiox6040085] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
185 van Koppen A, Verschuren L, van den Hoek AM, Verheij J, Morrison MC, Li K, Nagabukuro H, Costessi A, Caspers MPM, van den Broek TJ, Sagartz J, Kluft C, Beysen C, Emson C, van Gool AJ, Goldschmeding R, Stoop R, Bobeldijk-Pastorova I, Turner SM, Hanauer G, Hanemaaijer R. Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model. Cell Mol Gastroenterol Hepatol 2018;5:83-98.e10. [PMID: 29276754 DOI: 10.1016/j.jcmgh.2017.10.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
186 Asalla S, Mohareer K, Banerjee S. Small Molecule Mediated Restoration of Mitochondrial Function Augments Anti-Mycobacterial Activity of Human Macrophages Subjected to Cholesterol Induced Asymptomatic Dyslipidemia. Front Cell Infect Microbiol 2017;7:439. [PMID: 29067283 DOI: 10.3389/fcimb.2017.00439] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
187 Guo Y, Li JX, Wang YL, Mao TY, Chen C, Xie TH, Han YF, Tan X, Han HX. Yinchen Linggui Zhugan Decoction Ameliorates Nonalcoholic Fatty Liver Disease in Rats by Regulating the Nrf2/ARE Signaling Pathway. Evid Based Complement Alternat Med 2017;2017:6178358. [PMID: 28932253 DOI: 10.1155/2017/6178358] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
188 Tang Q, Jiang S, Jia W, Shen D, Qiu Y, Zhao Y, Xue B, Li C. Zoledronic acid, an FPPS inhibitor, ameliorates liver steatosis through inhibiting hepatic de novo lipogenesis. Eur J Pharmacol 2017;814:169-77. [PMID: 28843826 DOI: 10.1016/j.ejphar.2017.08.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
189 Yang JW, Kim HS, Choi Y, Kim Y, Kang KW. Therapeutic application of GPR119 ligands in metabolic disorders. Diabetes Obes Metab 2017;20:257-69. [DOI: 10.1111/dom.13062] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
190 Kolovou V, Bilianou H, Giannakopoulou V, Kalogeropoulos P, Mihas C, Kouris M, Cokkinos DV, Boutsikou M, Hoursalas I, Mavrogeni S, Katsiki N, Kolovou G. Five gene variants in nonagenarians, centenarians and average individuals. Arch Med Sci 2017;13:1130-41. [PMID: 28883855 DOI: 10.5114/aoms.2017.68942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
191 Rotimi OA, Rotimi SO, Duru CU, Ebebeinwe OJ, Abiodun AO, Oyeniyi BO, Faduyile FA. Acute aflatoxin B1 - Induced hepatotoxicity alters gene expression and disrupts lipid and lipoprotein metabolism in rats. Toxicol Rep 2017;4:408-14. [PMID: 28959666 DOI: 10.1016/j.toxrep.2017.07.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
192 Katsiki N, Purrello F, Tsioufis C, Mikhailidis DP. Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 2017;18:1243-60. [DOI: 10.1080/14656566.2017.1351946] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
193 Cheng X, Blake GM, Brown JK, Guo Z, Zhou J, Wang F, Yang L, Wang X, Xu L. The measurement of liver fat from single-energy quantitative computed tomography scans. Quant Imaging Med Surg 2017;7:281-91. [PMID: 28811994 DOI: 10.21037/qims.2017.05.06] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
194 Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017;71:17-32. [DOI: 10.1016/j.metabol.2017.02.014] [Cited by in Crossref: 163] [Cited by in F6Publishing: 142] [Article Influence: 32.6] [Reference Citation Analysis]
195 Leutner M, Göbl C, Schlager O, Charwat-Resl S, Wielandner A, Howorka E, Prünner M, Bozkurt L, Maruszczak K, Geyik H, Prosch H, Pacini G, Kautzky-Willer A. The Fatty Liver Index (FLI) Relates to Diabetes-Specific Parameters and an Adverse Lipid Profile in a Cohort of Nondiabetic, Dyslipidemic Patients. J Am Coll Nutr 2017;36:287-94. [PMID: 28506114 DOI: 10.1080/07315724.2016.1262802] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
196 Reccia I, Kumar J, Akladios C, Virdis F, Pai M, Habib N, Spalding D. Non-alcoholic fatty liver disease: A sign of systemic disease. Metabolism. 2017;72:94-108. [PMID: 28641788 DOI: 10.1016/j.metabol.2017.04.011] [Cited by in Crossref: 97] [Cited by in F6Publishing: 99] [Article Influence: 19.4] [Reference Citation Analysis]
197 Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism. 2017;72:57-65. [PMID: 28641784 DOI: 10.1016/j.metabol.2017.04.003] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 15.0] [Reference Citation Analysis]
198 Katsiki N, Athyros VG, Mikhailidis DP. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. Journal of Diabetes and its Complications 2017;31:521-2. [DOI: 10.1016/j.jdiacomp.2016.12.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
199 Katsiki N, Mikhailidis DP. Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial. Journal of Diabetes and its Complications 2017;31:1-3. [DOI: 10.1016/j.jdiacomp.2016.09.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
200 Athyros VG, Katsiki N, Mikhailidis DP. Response letter: Statins and non-alcoholic steatohepatitis. Metabolism 2017;66:e6. [PMID: 27842716 DOI: 10.1016/j.metabol.2016.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
201 Lee HJ, Lee CH, Kim S, Hwang SY, Hong HC, Choi HY, Chung HS, Yoo HJ, Seo JA, Kim SG. Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by 18F-fluorodeoxyglucose positron emission tomography. Metabolism. 2017;67:72-79. [PMID: 28081780 DOI: 10.1016/j.metabol.2016.11.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
202 Athyros VG, Katsiki N, Mikhailidis DP. Statins and non-alcoholic steatohepatitis. Metabolism 2017;66:e1-2. [PMID: 27836113 DOI: 10.1016/j.metabol.2016.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
203 Bae JS, Park JM, Lee J, Oh BC, Jang SH, Lee YB, Han YM, Ock CY, Cha JY, Hahm KB. Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice. Metabolism 2017;66:32-44. [PMID: 27923447 DOI: 10.1016/j.metabol.2016.10.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
204 Du T, Sun X, Yuan G, Zhou X, Lu H, Lin X, Yu X. Lipid phenotypes in patients with nonalcoholic fatty liver disease. Metabolism 2016;65:1391-8. [DOI: 10.1016/j.metabol.2016.06.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
205 Katsiki N, Mantzoros CS. Statins in relation to adiponectin: A significant association with clinical implications. Atherosclerosis 2016;253:270-2. [PMID: 27567030 DOI: 10.1016/j.atherosclerosis.2016.08.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
206 Canbay A, Gerken G, Bechmann LP. [Hepatic steatosis : Differential diagnostics and current aspects]. Internist (Berl) 2016;57:879-92. [PMID: 27510334 DOI: 10.1007/s00108-016-0112-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
207 Polyzos SA, Bugianesi E, Kountouras J, Mantzoros CS. Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists. Metabolism 2017;66:64-8. [PMID: 27594084 DOI: 10.1016/j.metabol.2016.08.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]